<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2020-1-3678</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-3678</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Риск венозных тромбоэмболических осложнений у пациентов с хронической сердечной недостаточностью</article-title><trans-title-group xml:lang="en"><trans-title>The risk of venous thromboembolism in patients with heart failure</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0678-4224</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вереина</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Vereina</surname><given-names>N. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вереина Наталья Константиновна — доктор медицинских наук, профессор кафедры факультетской терапии</p><p>Челябинск</p></bio><bio xml:lang="en"/><email xlink:type="simple">vereinanata@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4729-6606</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агасян</surname><given-names>Д. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Agasyan</surname><given-names>D. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агасян Диана Гарниковна— студент 6 курса педиатрического факультета</p><p>Челябинск</p></bio><bio xml:lang="en"/><email xlink:type="simple">agasyan.dianochka@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0952-6856</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чулков</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Chulkov</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чулков Василий Сергеевич— доктор медицинских наук, профессор кафедры факультетской терапии</p><p>Челябинск</p></bio><bio xml:lang="en"/><email xlink:type="simple">vschulkov@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ Южно-Уральский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2019</year></pub-date><volume>25</volume><issue>1</issue><fpage>3678</fpage><lpage>3678</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вереина Н.К., Агасян Д.Г., Чулков В.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Вереина Н.К., Агасян Д.Г., Чулков В.С.</copyright-holder><copyright-holder xml:lang="en">Vereina N.K., Agasyan D.G., Chulkov V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/3678">https://russjcardiol.elpub.ru/jour/article/view/3678</self-uri><abstract><sec><title>Цель</title><p>Цель. Провести количественную оценку риска венозных тромбоэмболических осложнений у госпитализированных пациентов в зависимости от выраженности хронической сердечной недостаточности.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Исследование по типу «поперечного среза». В исследование были включены 132 пациента, госпитализированные в кардиологическое отделение МАУЗ ОТКЗ № 1 г. Челябинска в 2019 году, которые распределены на 2 группы: группа 1 (48 человек) – пациенты, имеющие I и II ФК ХСН; группа 2 (84 человека) – с III и IV ФК ХСН. Суммарная количественная оценка риска венозных тромбоэмболических осложнений проводилась по шкале J. Caprini.</p></sec><sec><title>Результаты</title><p>Результаты. Все пациенты, госпитализированные в кардиологическое отделение, независимо от функционального класса ХСН, относились к группе умеренного и высокого риска ВТЭО и нуждались в медикаментозной антикоагулянтной профилактике. В группе с ХСН I–II ФК высокий риск имели 85% больных, а с III и IV ФК – 97,6 % больных, при этом средний балл ≥ 10 был у каждого пятого пациента. Фибрилляцию предсердий, требующую длительной антикоагулянтной терапии, имело 51,5% пациентов. Абсолютных противопоказаний для назначения парентеральных антикоагулянтов в профилактических дозах на момент госпитализации в исследуемой популяции не выявлено.</p></sec><sec><title>Заключение</title><p>Заключение. Все пациенты, госпитализированные в кардиологическое отделение, имели умеренный и высокий риск ВТЭО по шкале J. Caprini вне зависимости от функционального класса ХСН. Показания для длительной антикоагулянтной терапии имели более половины пациентов. Остальные больные нуждались в назначении профилактических доз парентеральных антикоагулянтов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To quantify the risk of venous thromboembolism (VTE) in hospitalized patients, depending on the severity of heart failure (HF).</p></sec><sec><title>Material and methods</title><p>Material and methods. Current cross-sectional study included 132 patients hospitalized in the cardiology department in 2019. All participants were divided into 2 groups: group 1 (n=48) — patients with class I-II HF; group 2 (n=84) — patients with class III-IV HF. A total quantitative assessment of the VTE risk was carried out according to the Caprini risk scoring method.</p></sec><sec><title>Results</title><p>Results. All patients hospitalized in the cardiology department, regardless of HF class, had a moderate and high risk of VTE and required prophylactic anticoagulation. High VTE risk had 85% of patients with class I-II HF; 97,6% — patients with a class III-IV HF. Mean score of ≥10 was observed in every fifth patient. Atrial fibrillation requiring long-term anticoagulant therapy was observed in 51,5% of patients. There were no absolute contraindications for parenteral prophylactic anticoagulation at the time of hospitalization in the study population.</p></sec><sec><title>Conclusion</title><p>Conclusion. All patients admitted to the cardiology department had a moderate and high according to the Caprini risk score, regardless of HF class. More than half of the patients had indications for long-term anticoagulant therapy. The remaining patients required the parenteral prophylactic anticoagulation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>венозные тромбоэмболические осложнения</kwd><kwd>профилактика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>venous thromboembolism</kwd><kwd>prevention</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med.2014;127(9):829-39. e5. doi:10.1016/j.amjmed.2014.03.041.</mixed-citation><mixed-citation xml:lang="en">Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med.2014;127(9):829-39. e5. doi:10.1016/j.amjmed.2014.03.041.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Аверков ОВ, Шевченко ИВ, Мирилашвили ТШ, и др. Венозные тромбозы и эмболии у больных с сердечной недостаточностью. Кардиоваскулярная терапия и профилактика. 2011;10(4):101-6. doi:10.15829/1728-8800-2011-4-101-106.</mixed-citation><mixed-citation xml:lang="en">Averkov OV, Shevchenko IV, Mirilashvili TS, et al. Venous thromboembolism in patients with heart failure. Cardiovascular Therapy and Prevention. 2011;10(4):101-6. (In Russ.) doi:10.15829/1728-8800-2011-4-101-106.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tang L, Wu Y-Y, Lip GYH, et al. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 2016;3(1):E30-Е44. doi:10.1016/S2352-3026(15)00228-8.</mixed-citation><mixed-citation xml:lang="en">Tang L, Wu Y-Y, Lip GYH, et al. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 2016;3(1):E30-Е44. doi:10.1016/S2352-3026(15)00228-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Бокерия ЛА, Затевахин ИИ, Кириенко АИ, и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнении. Флебология. 2015;9(4):2-52.</mixed-citation><mixed-citation xml:lang="en">Bokeriya LA, Zatevakhin II, Kiriyenko AI, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTE). Flebologiya. 2015;9(4):2-52 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-8. doi:10.1016/j.disamonth.2005.02.003.</mixed-citation><mixed-citation xml:lang="en">Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-8. doi:10.1016/j.disamonth.2005.02.003.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев ВЮ, Фомин ИВ, Агеев ФТ, и др. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.18087/cardio.2475.</mixed-citation><mixed-citation xml:lang="en">Mareev VY, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shantsila E, Gregory YH, Lip GYH. Thrombotic Complications in Heart Failure An Underappreciated Challenge. Circulation. 2014; 130:387-9. doi:10.1161/CIRCULATIONAHA.114.011353.</mixed-citation><mixed-citation xml:lang="en">Shantsila E, Gregory YH, Lip GYH. Thrombotic Complications in Heart Failure An Underappreciated Challenge. Circulation. 2014; 130:387-9. doi:10.1161/CIRCULATIONAHA.114.011353.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bounameaux H, Agnelli G. Symptoms and clinical relevance: a dilemma for clinical trials on prevention of venous thromboembolism. Thromb Haemost. 2013;109:585-8. doi:10.1160/TH12-08-0627.</mixed-citation><mixed-citation xml:lang="en">Bounameaux H, Agnelli G. Symptoms and clinical relevance: a dilemma for clinical trials on prevention of venous thromboembolism. Thromb Haemost. 2013;109:585-8. doi:10.1160/TH12-08-0627.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Basnet S, Dhital R, Tharu B, et al. Yearly trend of acute venous thromboembolism in patients admitted with heart failure in the United States. Journal of Community Hospital Internal Medicine Perspectives. 2019;9(4):287-9. doi:10.1080/20009666.2019.1634408.</mixed-citation><mixed-citation xml:lang="en">Basnet S, Dhital R, Tharu B, et al. Yearly trend of acute venous thromboembolism in patients admitted with heart failure in the United States. Journal of Community Hospital Internal Medicine Perspectives. 2019;9(4):287-9. doi:10.1080/20009666.2019.1634408.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu R, Hu Y, Tang L. Reduced cardiac function and risk of venous thromboembolism in Asian countries. Thrombosis J. 2017;15:12. doi:10.1186/s12959-017-0135-3.</mixed-citation><mixed-citation xml:lang="en">Zhu R, Hu Y, Tang L. Reduced cardiac function and risk of venous thromboembolism in Asian countries. Thrombosis J. 2017;15:12. doi:10.1186/s12959-017-0135-3.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation &amp; Fibrinolysis. 2003;14(4):341-6. doi:10.1097/00001721-200306000-00004.</mixed-citation><mixed-citation xml:lang="en">Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation &amp; Fibrinolysis. 2003;14(4):341-6. doi:10.1097/00001721-200306000-00004.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77. doi:10.1056/NEJMoa1110899.</mixed-citation><mixed-citation xml:lang="en">Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77. doi:10.1056/NEJMoa1110899.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-23. doi:10.1056/NEJMoa1111096.</mixed-citation><mixed-citation xml:lang="en">Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-23. doi:10.1056/NEJMoa1111096.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534-44. doi:10.1056/NEJMoa1601747.</mixed-citation><mixed-citation xml:lang="en">Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534-44. doi:10.1056/NEJMoa1601747.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Al Yami MS, Kurdi S, Abraham I. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment. J Blood Med. 2018;9:25-34. doi:10.2147/JBM.S149202.</mixed-citation><mixed-citation xml:lang="en">Al Yami MS, Kurdi S, Abraham I. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment. J Blood Med. 2018;9:25-34. doi:10.2147/JBM.S149202.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
